Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Pleyer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|May 17, 2018
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemiaChristopher Pleyer, Adrian Wiestner, Clare Sun
Clinical Nephrology. Case Studies|October 19, 2017
Lysozyme amyloidosis - a case report and review of the literatureChristopher Pleyer, Jan Flesche, Fahad Saeed
Leukemia & Lymphoma|September 21, 2023
Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLLEmily Tomasulo, Shira Paul, Rui Mu, et al.
Leukemia & Lymphoma|June 9, 2020
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitorsChristopher Pleyer, Clare Sun, Sanjal Desai, et al.
Blood|December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccinesChristopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Blood Advances|February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLLChristopher Pleyer, Kerry J Laing, Mir A Ali, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|May 17, 2018
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemiaChristopher Pleyer, Adrian Wiestner, Clare Sun
Clinical Nephrology. Case Studies|October 19, 2017
Lysozyme amyloidosis - a case report and review of the literatureChristopher Pleyer, Jan Flesche, Fahad Saeed
Leukemia & Lymphoma|September 21, 2023
Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLLEmily Tomasulo, Shira Paul, Rui Mu, et al.
Leukemia & Lymphoma|June 9, 2020
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitorsChristopher Pleyer, Clare Sun, Sanjal Desai, et al.
Blood|December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccinesChristopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Blood Advances|February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLLChristopher Pleyer, Kerry J Laing, Mir A Ali, et al.
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Pageof 1